Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsEkonomimTurkish, translatedFiled 36 h ago

How true is the claim that "weight loss injections cause blindness"?

Original headline“Zayıflama iğneleri kör ediyor” iddiası ne kadar doğru?

Open the sourceReported by Ekonomim, ekonomim.com, 20 November 2026

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

The U.S. Food and Drug Administration (FDA) has asked manufacturers of GLP-1 obesity and diabetes drugs to add a warning about a serious eye disease to their prescribing labels, a move that has reignited debate over whether popular weight-loss injections can cause vision loss. The label change, requested on November 9, 2026, follows scrutiny of the drugs, which are widely used in the fight against obesity and diabetes. The FDA action matters because GLP-1 therapies have become a massive market, and a formal warning could affect how doctors and patients weigh the risks of treatment. What to watch next is how manufacturers respond to the labeling request and whether further regulatory guidance or new data on the eye risk emerges.

Muhabbit's AI wrote this summary in its own words from Ekonomim's report and translated it from Turkish. It can get details wrong, so check the source.

Named in this story

GLP-1 drugs, FDA